BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Jennifer E. Van Eyk
Professor of Medicine, Biological Chemistry and
Biomedical Engineering
eRA COMMONS USER NAME (credential, e.g., agency login)
JVANEYK1
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
University of Waterloo, Waterloo, Canada
University of Alberta, Edmonton, Alberta, Canada
University of Heidelberg, Heidelberg, Germany
University of Alberta, Edmonton, Alberta, Canada
University of Illinois at Chicago, Chicago, USA
B.Sc.
Ph.D.
P.D. Fellow
Res. Assoc.
P.D. Fellow
1982
1991
1992
1995
1996
Biology & Chemistry
Biochemistry
Physiology/Cardiology
Biochemistry/Muscle
Biochemistry/Cardiology
A. Personal Statement
My central philosophy is that compelling biological and clinical questions drive innovation through
development, optimization and adaption of proteomic technologies, functional analysis, and large-scale data
handling. My primary research focuses i) on understanding the molecular mechanism underlying acute and
chronic disease and treatment therapies and ii) in the development of clinically robust circulating biomarkers.
My laboratory has become a leader in the field of proteomics especially in cardiovascular disease, integrating
cutting-edge proteomics and driving innovation which is applicable across all human disease. We have
developed technological pipelines to quantify protein isoform and PTM changes of proteins in disease
pathways. Our group has also been undertaking the development of multiple reaction monitoring assays, a
MS-based quantitative method, for a number of membrane proteins and signaling pathways to determine their
absolute concentration. These sophisticated assays allow multiplexing of many proteins (and their PTMs).
B. Positions and Honors
1996–2001
Assistant Professor, Depart. Physiology (cross-appt. Biochemistry), Queen’s University, Canada
2001–2003
Associate Professor (Tenured) Department Physiology, Queen’s University, Kingston, Canada
2003–pres.
Assoc. Prof. Depts. Medicine, Biomed. Eng., and Biol. Chem., Johns Hopkins University, MD
2003–pres.
Director, Johns Hopkins Bayview Proteomic Center, Johns Hopkins University, MD
2003–pres.
Director, NHLBI Innovation Proteomic Group, Johns Hopkins University, MD.
2007–pres.
Director, Johns Hopkins CTSA/ITCR Biomarker Development Group, Johns Hopkins University
2007–pres.
Professor, Depts. Medicine, Biomed. Eng., Biol. Chem., Johns Hopkins University, MD
Honors
1996–2001 Heart and Stroke Foundation of Canada Scholarship (graduate student)
1998
Canadian Foundation for Innovation Scholar
2000
Chancellor’s Research Award, Queen’s University, Canada
2000
PREA (Premier’s Research Excellence Award), Ontario Government, Canada
2000–pres.
Editorial Board member, Circulation Research
2000
AHA Top 10 research papers in 2000 for Murphy et al., Science.
2001
Heart and Stroke of Ontario Career Investigator Award
2001
Fellow of American Heart Association (FAHA) for the Basic Science Council
2001
Basmajian Top Research Award (Queen’s University, Faculty of Medicine)
2002–pres.
Editorial Board, Proteomics and Associate Editor, Technical Brief sections, Proteomics
2003
NIH (NHLBI) Member of WG for Heart Failure and member of WG for Clinical Proteomics
2003–pres.
ISHR (International Society of Heart Research) North American Section Board Member
2004–2008
AHA Basic Council Member-At-Large
2004
NIH (NIESH) Member of Proteomic Advisory Group
2005
FDA site visit team – assessment of Clinical Proteomics, and Labs of Immunology/Chemistry
2005
Co-chair NHBLI workshop entitled “The next Step: population studies in the “OMIC” age”
2006
Member of NHLBI Strategic Plan Cardiovascular Working Group on Emerging Technologies
2006
Beckman Sponsored lecture, British Society of Proteome Research Meeting
2007–2010
2007–pres.
2008–pres.
2008–2012
2009–pres.
2009–pres.
2009–2010
2009–pres.
2009–2014
2009
2010
2010
2010
2010
2011
2011
AHA Functional Genomics and Translational Science (IWG), chair (2008-2010)
Associate editorial Broad, Proteomics, Clinical Applications
Editorial Board, Circulation: Genetics
NHBLI grant review panel permanent member (MIM)
Consulting editor, Circulation Research
Metabolic Disorders Steering Committee of Foundation for the NIH (FNIH) Biomarker
Consortium, Atherosclerosis Biomarker Outcomes Working Group
Institute of Medicine (National Academy), committee member on the Quantification of
Biomarkers as Surrogate Endpoints
International Society of Heart Research (ISHR), North American Section, Secretary
Research Council Member, AHA mid-Atlantic
AHA top 10 research papers of 2009 granted to Matt et al., Circ. 2009:120:526-32.
Expert lecturer for Institute of Medicine (National Academy) for committee on accelerating rare
diseases research and orphan product development
Dean’s lecture, Johns Hopkins University
Fellow of the International Society of Heart Research (ISHR)
Fellow of the American Heart Association in Functional Genomics and Translational Biology
Keynote address in CNHUPO (China HUPO) on novel approaches in biomarker development
The David Grimm Lecture, Ottawa Heart, Ottawa, Canada
C. Selected Peer-reviewed Publications
Total 163 peer-reviewed articals/20 book chapters/2 books (19 papers in 2010, 19 in 2011, 7 in 2012)
1. Murphy AM, Kogler H, Georgakopoulos D, McDonough JL, Kass DA, Van Eyk JE, Marban E. Transgenic
mouse model of stunned myocardium. Science 2000;287:488. PMID: 10642551
2. Xu W, Liu Y,Wang S, McDonald T, Van Eyk JE, Sidor A, O'Rourke B. Cytoprotective role of the Caactivated K+ channel in cardiac inner mitochondrial membrane. Science 2002;298: 1029. PMID: 12411707
3. Mathivanan S et al., Human Proteinpedia enables sharing of human protein data.Nat Biotechnol. 2008;
26:164-7. PMID: 18259167
4. Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, Ochi T, Zeller K, De Marzo AM, Van Eyk JE,
Mendell JT, Dang CV. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine
metabolism. Nature 2009: 458:762. PMID: 2729443
5. Fu Z, Wang M, Gucek M, Zhang J, Wu J, Jiang L, Monticone RE, Khazan B, Telljohann R, Mattison J,
Sheng S, Cole RN, Spinetti G, Pintus G, Liu L, Kolodgie FD, Virmani R, Spurgeon H, Ingram DK, Everett
AD, Lakatta E, Van Eyk JE. Milk fat globule protein-epidermal growth factor-8: a pivotal relay element
within the angiotensin II and monocyte chemoattractant protein-1 signaling cascade mediating vascular
smooth muscle cells invasion, Circ. Res, 2009:104:1337. PMID: 19443842
6. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer
J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Dietz HC; the GenTAC Consortium. Circulating
transforming growth factor-beta in Marfan Syndrome. Circ. 2009:120:526. PMID: 19635970
Editorial: Braverman AC. Transforming Growth Factor-beta. A Biomarker in Marfan Syndrome? .
7. Gundry RL, Raginski K, Tarasova Y, Tchernyshyov I, Bausch-Fluck D, Elliott ST, Boheler KR, Van Eyk JE
Wollscheid B. The Mouse C2C12 Myoblast Cell Surface N-Linked Glycoprotein Subproteome. Mol. Cell
Prot. 2009;8:2555.PMC27773721
8. Agnetti G, Kaludercic N, Kane LA, Elliott ST, Guo Y, Chakir K, Samantapudi D, Paolocci N, Tomaselli GT,
Kass DA, Van Eyk JE. Modulation of Mitochondrial Proteome and Improved Mitochondrial Function by Biventricular Pacing of Dyssynchronous Failing Hearts. Circ: Genetics, 2009:3:78. PMC2921909
9. Kane KA, Youngman MJ, Jensen RE, Van Eyk JE. Phosphorylation of the F1Fo ATP synthase β subunit:
Functional and structural consequences assessed in a model system. Circ Res. 2010:106:106504.
PMC2835499. Paper was the Editor’s pick
10. Gundry RL, White MY, Murray CI, Kane LA, Fu Q, Stanley BA, Van Eyk JE. Preparation of proteins and
peptides for mass spectrometry analysis in a bottom-up proteomics workflow. Curr Protoc Mol Biol.
2009;Chapter 10:Unit10.25. PMC2905857
11. Stastna M, Chimenti I, Marbán E, Van Eyk JE. Identification and functionality of proteomes secreted by rat
cardiac stem cells and neonatal cardiomyocytes. Proteomics. 2010,10:245. PMCID: PMC2844639
12. Murray CI, Kane LA, Uhrigshardt H, Wang SB, Van Eyk JE. Site-mapping of in vitro S-nitrosation in cardiac
mitochondria: implications for cardioprotection. Mol Cell Proteomics 2011;10:In press PMC3047159
13. Wang SB, Foster DB, Rucker J, O'Rourke B, Kass DA, Van Eyk JE. Redox Regulation of Mitochondrial
ATP Synthase: Implications for Cardiac Resynchronization Therapy. Circ. Res. In press.
14. Murray CI, Uhrigshardt H, O'Meally RN, Cole RN, Van Eyk JE. Identification and quantification of Snitrosylation by cysteine reactive tandem mass Tag switch assay. Mol Cell Proteomics. In press.
15. Zhang P, Ji W, dos Remedios CG, Kirk JA, Kass DA, Van Eyk JE*, Murphy AM (*corresponding author).
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human
heart. Circ. In press.
Books:
1. J.E. Van Eyk and M. Dunn. Genomic and Proteomic Analysis of Cardiovascular Disease: molecular
mechanism, therapeutic targets and diagnostics. Wiley-VCH Publishers, 2003;
2. J.E. Van Eyk and M. Dunn. Clinical Proteomics: from Diagnosis to Therapy, Wiley-VCH Publishers, 2007\
Guest editor for proteomic or CVD series: 2001–2003.Circ Res (5 articles); 2005.J. Physiology (London) (5
articles); 2008 Proteomics: Clinical Application volume (July); 2010 Circulation Research (5 articles); 2011
Circulation Genetics educational series on Proteomics technology (13 articles).
Patent Applications: 4 patent, 12 applications in proteomic tools and software and protein biomarkers
D. Ongoing Research Support
1. ARRA-R01HL85434 (J. Van Eyk) no cost extension
07/01/09 – 06/30/12
“Proteomics of Stem Cell”
The main goal is to identify the protein changes in embryonic stem cells upon initiations of differentiation.
2. 1U54RR023561-01A1 (D. Ford)
09/30/07 – 05/31/12
“Institutional Clinical and Translational Science Award”
The main goal is to enhance and facilitate clinical and translational science.
Role: PI of Biomarker Development Center.
3. P01 HL77189-01 (D. Kass) renewal
09/01/10 – 08/31/15
“Pathobiology of Cardiac Dysynchrony and Resynchronization”
The main goal is to determine the molecular mechanism that underlies CRT therapy.
Role: PI of a project on mitochondria modification in CRT and PI of proteomics and genomic core.
4. 1R01 HL101235-01 (O’Rourke, co-PIs Bers, Lothar, Trayanova, Van Eyk) 06/01/10 – 05/30/15
MItochondrial Dysfunction in Cardiac Hypertrophy and Failure
The goal is to determine how Ca2+dynamics contribute to impaired mitochondria with heart failure.
Role: PI of project on PTM of mitochondrial proteins.
5. NHLBI-HV-10-05 (2) (J. Van Eyk)
08/15/2011 – 08/14/15
The Johns Hopkins Innovation Proteomics Center in Heart Failure.
Role: PI of contract (12 PIs) to develop and apply innovative mass spectrometry based
PTM capture methods in HF.
6. PO1 HL10026 (G. Hart, co-PI Van Eyk)
06/01/11 – 05/30/18
“Glycoconjungates and Cardiovascular Disease”
The goal is to develop and apply new proteomic methods in glycyobiology.
Role: co-PI of project involving cell-environment interface of myocytes and fibroblasts and PI of MS core.
7.U01 DK085689-0 (J. Coresh, J. Van Eyk)
09/30/09 - 04/30/14
“Proteomic Biomarkers of Chronic Kidney Disease”
The main goal is to identify and quantify potential serum and urine biomarkers for CKD.
Role: Co-PI and will direct proteomic
8. R21 (J. Van Eyk, D. Kass)
09/01/11- 08/31/13
“Novel post-translational modification in heart failure”
The goal is to determine and quantify the proteins that become citrullinated with heart failure and
the regulation of the enzymes involved.
Role: PI to over see project